EZH2 and cancer: Work using RNAi knockdown and small molecule inhibitors of EZH2 has shown that EZH2 is required for the proliferation of EZH2 mutant lymphoma cells, SMARCB1-deficient MRT cells and cells from other cancer types [6, 7, 19–23].